Claudio Laudani: A Striking Geographic Heterogeneity in Aspirin and Clopidogrel Comparison for MACE Prevention
Claudio Laudani, Former Postdoctoral Researcher at UF Health Jacksonville, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in European Heart Journal, adding:
”Recent studies have suggested that clopidogrel may be superior to aspirin for secondary prevention of major adverse cardiovascular events (MACE).
However, most of the available evidence comes from trials conducted in East Asia, raising important questions about the generalizability of these findings to Western populations.
In our study, we compared aspirin and clopidogrel according to patient ethnicity and found a striking geographic heterogeneity in treatment effect.
The apparent benefit of clopidogrel was driven almost entirely by East Asian trials, whereas results from Western studies were largely neutral.
Among East Asian patients, clopidogrel was associated with:
- 24% reduction in MACE
- 27% reduction in NACE
- 30% reduction in myocardial infarction
By contrast, no significant differences were observed among non–East Asian patients, with significant interaction observed for both MACE and all-cause mortality.
These findings underscore the need for caution when extrapolating results across populations.
Differences in drug metabolism, ischemic risk, and bleeding profiles may substantially influence the balance between aspirin and clopidogrel in different ethnic groups.
Further global studies are needed to better define the optimal antiplatelet strategy across diverse patient populations.”
Title: Aspirin vs clopidogrel in chronic coronary syndromes: a meta-analysis of ethnic differences Get access Arrow
Authors: Claudio Laudani, Giovanni Occhipinti, Francesco Costa, Domenico D’Amario, Tullio Palmerini, Sebastiano Sciarretta, Charles Michael Gibson, Behnood Bikdeli, Felicita Andreotti, Young-Hoon Jeong, Takeshi Kimura, Diana A. Gorog, Dirk Sibbing, Davide Capodanno, Jurrien ten Berg, Raffaele De Caterina, Mattia Galli
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 1, 2026, 07:52Marc Carrier: TRIM-Line Trial Evaluates VTE Prevention in Cancer
-
Oct 1, 2026, 07:29Ariela Marshall: New Guidelines Provide Updated Recommendations for Iron Deficiency Diagnosis
-
Sep 30, 2026, 22:28Recent Mechanical Risk Factors and Young-Onset Cryptogenic Ischemic Stroke – American Heart Association International
-
Sep 30, 2026, 22:22Expert Consensus on Inferior Vena Cava Thrombosis – Thrombosis and Haemostasis Journal
-
Sep 30, 2026, 22:21Markus Abeln: How Platelets and Complement Shape Placental Blood Flow
-
Sep 30, 2026, 22:19Fatma Al Arbawi: Studying Blood Clot Mechanics to Understand Aspirin Resistance and Thrombosis
-
Sep 30, 2026, 22:17Sudhir Kumar: Stroke is a Medical Emergency – and Every Minute Matters
-
Sep 30, 2026, 22:15Luisa Medeiros Visentini: Our Research on Cognitive Impairment After CVT Cited in the International Journal of Stroke
-
Sep 30, 2026, 21:50Jagat Narula: Connecting Cardiovascular Health and Sickle Cell Disease on World Heart Day 2026